Literature DB >> 20827265

Pharmacologic development of male hormonal contraceptive agents.

M Y Roth1, J K Amory.   

Abstract

The world population continues to increase dramatically despite the existence of contraceptive technology. The use of male hormonal contraception may help in preventing un intended pregnancies and managing future population growth. Male hormonal contraception relies on the administration of exogenous hormones to suppress spermatogenesis. Clinical trials have tested several regimens using testosterone, alone or in combination with a progestin. These regimens were shown to be >90% effective in preventing conception and were not associated with serious adverse events.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20827265      PMCID: PMC3212391          DOI: 10.1038/clpt.2010.103

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  30 in total

1.  Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies.

Authors:  H M Behre; K Abshagen; M Oettel; D Hübler; E Nieschlag
Journal:  Eur J Endocrinol       Date:  1999-05       Impact factor: 6.664

2.  Testosterone gel combined with depomedroxyprogesterone acetate is an effective male hormonal contraceptive regimen and is not enhanced by the addition of a GnRH antagonist.

Authors:  Stephanie T Page; John K Amory; Bradley D Anawalt; Michael S Irwig; Andrew T Brockenbrough; Alvin M Matsumoto; William J Bremner
Journal:  J Clin Endocrinol Metab       Date:  2006-08-29       Impact factor: 5.958

3.  Contraceptive failure rates in France: results from a population-based survey.

Authors:  C Moreau; J Trussell; G Rodriguez; N Bajos; J Bouyer
Journal:  Hum Reprod       Date:  2007-06-28       Impact factor: 6.918

4.  Nestorone: a progestin with a unique pharmacological profile.

Authors:  N Kumar; S S Koide; Y Tsong; K Sundaram
Journal:  Steroids       Date:  2000 Oct-Nov       Impact factor: 2.668

5.  Rates of suppression and recovery of human sperm output in testosterone-based hormonal contraceptive regimens.

Authors:  Lam P Ly; Peter Y Liu; David J Handelsman
Journal:  Hum Reprod       Date:  2005-04-28       Impact factor: 6.918

6.  Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis.

Authors:  Peter Y Liu; Ronald S Swerdloff; Peter D Christenson; David J Handelsman; Christina Wang
Journal:  Lancet       Date:  2006-04-29       Impact factor: 79.321

7.  A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men.

Authors:  Yi-Qun Gu; Xing-Hai Wang; Dwo Xu; Lin Peng; Li-Fa Cheng; Ming-Kong Huang; Zhen-Jia Huang; Gui-Yuan Zhang
Journal:  J Clin Endocrinol Metab       Date:  2003-02       Impact factor: 5.958

8.  AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function.

Authors:  C Steidle; S Schwartz; K Jacoby; T Sebree; T Smith; R Bachand
Journal:  J Clin Endocrinol Metab       Date:  2003-06       Impact factor: 5.958

Review 9.  Advances in male contraception.

Authors:  Stephanie T Page; John K Amory; William J Bremner
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

10.  Male hormonal contraception: effects of injections of testosterone undecanoate and depot medroxyprogesterone acetate at eight-week intervals in chinese men.

Authors:  Yi-Qun Gu; Jian-Sun Tong; Ding-Zhi Ma; Xing-Hai Wang; Dong Yuan; Wen-Hao Tang; William J Bremner
Journal:  J Clin Endocrinol Metab       Date:  2004-05       Impact factor: 5.958

View more
  8 in total

1.  Identification of adenine nucleotide translocase 4 inhibitors by molecular docking.

Authors:  Wai-Yee Leung; Takashi Hamazaki; David A Ostrov; Naohiro Terada
Journal:  J Mol Graph Model       Date:  2013-09-04       Impact factor: 2.518

2.  Testicular ultrastructure and hormonal changes following administration of tenofovir disoproxil fumarate-loaded silver nanoparticle in type-2 diabetic rats.

Authors:  Samuel Oluwaseun Olojede; Sodiq Kolawole Lawal; Oluwaseun Samuel Faborode; Ayobami Dare; Okikioluwa Stephen Aladeyelu; Roshila Moodley; Carmen Olivia Rennie; Edwin Coleridge Naidu; Onyemaechi Okpara Azu
Journal:  Sci Rep       Date:  2022-06-10       Impact factor: 4.996

3.  The apical ectoplasmic specialization-blood-testis barrier functional axis is a novel target for male contraception.

Authors:  Ka-Wai Mok; Pearl P Y Lie; Dolores D Mruk; Jayakanthan Mannu; Premendu P Mathur; Bruno Silvestrini; C Yan Cheng
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

Review 4.  The practical management of testosterone deficiency in men.

Authors:  Antonio Aversa; Abraham Morgentaler
Journal:  Nat Rev Urol       Date:  2015-10-13       Impact factor: 14.432

5.  The emerging role of insulin-like growth factors in testis development and function.

Authors:  Richard J Griffeth; Vanessa Bianda; Serge Nef
Journal:  Basic Clin Androl       Date:  2014-08-18

Review 6.  The future of male contraception: a fertile ground.

Authors:  Iyad Khourdaji; Jacqueline Zillioux; Kevin Eisenfrats; Daniel Foley; Ryan Smith
Journal:  Transl Androl Urol       Date:  2018-05

7.  Use of Exogenous Testosterone for the Treatment of Male Factor Infertility: A Survey of Nigerian Doctors.

Authors:  Olufunmilade Akinfolarin Omisanjo; Stephen Odunayo Ikuerowo; Moruf Adekunle Abdulsalam; Sheriff Olabode Ajenifuja; Khadijah Adebisi Shittu
Journal:  Int J Reprod Med       Date:  2017-08-29

8.  RiboTag analysis of actively translated mRNAs in Sertoli and Leydig cells in vivo.

Authors:  Elisenda Sanz; Ryan Evanoff; Albert Quintana; Elizabeth Evans; Jeremy A Miller; Chemyong Ko; Paul S Amieux; Michael D Griswold; G Stanley McKnight
Journal:  PLoS One       Date:  2013-06-11       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.